Reportedly, Drugmakers Amgen Inc. (AMGN) and AstraZeneca Plc (AZN) announced that a crucial trial found that their experimental medication tezepelumab largely reduced asthma attacks for people suffering from severe forms of the respiratory condition compared to a placebo. The patients were also receiving standard care, medium- or high-dose inhaled corticosteroids, and at least one other controller medication.
“The key thing is that tezepelumab also seems to work in the low eosinophil patient group, which could help it differentiate from Regeneron’s Dupixent and AstraZeneca’s Fasenra, both of which are indicated for the ‘eosinphilic phenotype’,” stated Mizuho analyst Salim Syed a research note, referring to currently available asthma drugs.
The drugmakers informed that tezepelumab was well received by trial patients with no major differences in safety results compared to the placebo. The drug also showed results in a subgroup of patients with low levels of a type of white blood cell, known as eosinophil, related to swelling and narrowing of airways.
Amgen informed that the full results from the trial will be presented at an upcoming medical meeting.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.